NADAC acquisition cost data for ACARBOSE 25 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 47781034001 | $0.1839 | 2022-02-23 | Rx |
| 47781034001 | $0.1839 | 2022-02-23 | Rx |
| 47781034001 | $0.1839 | 2022-02-23 | Rx |
| 00054014025 | $0.1795 | 2022-12-21 | Rx |
| 23155014701 | $0.1795 | 2022-12-21 | Rx |
| 64380075806 | $0.1795 | 2022-12-21 | Rx |
| 69543012010 | $0.1795 | 2022-12-21 | Rx |
| 69543012011 | $0.1795 | 2022-12-21 | Rx |
| 00054014025 | $0.1795 | 2022-12-21 | Rx |
| 23155014701 | $0.1795 | 2022-12-21 | Rx |
Generic: Acarbose | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $8.8M | 173,977 | 44,062 | $0.3439 |
| 2020 | $10.7M | 185,085 | 43,961 | $0.3750 |
| 2021 | $10.7M | 180,238 | 44,200 | $0.3708 |
| 2022 | $10.1M | 174,307 | 43,168 | $0.3570 |
| 2023 | $9.8M | 169,742 | 42,919 | $0.3504 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $1.8M | 29,665 | 7,732 |
| New York | $1.5M | 28,578 | 5,836 |
| Texas | $731.5K | 11,780 | 3,545 |
| Florida | $527.0K | 8,782 | 2,646 |
| New Jersey | $467.5K | 6,853 | 1,786 |
| Illinois | $358.2K | 5,736 | 1,555 |
| Pennsylvania | $322.5K | 6,468 | 1,487 |
| Ohio | $306.2K | 5,504 | 1,391 |
| Michigan | $230.8K | 3,657 | 1,033 |
| Georgia | $222.0K | 4,034 | 1,107 |
| Massachusetts | $219.6K | 3,272 | 792 |
| Alabama | $209.9K | 3,336 | 901 |
| Puerto Rico | $191.2K | 3,760 | 788 |
| Virginia | $179.7K | 3,220 | 916 |
| North Carolina | $171.2K | 3,010 | 852 |
| Washington | $169.9K | 2,712 | 774 |
| Tennessee | $151.7K | 2,696 | 717 |
| Arizona | $140.5K | 2,344 | 744 |
| Indiana | $137.3K | 2,275 | 665 |
| Louisiana | $126.7K | 2,686 | 738 |
| Missouri | $124.9K | 2,240 | 578 |
| Maryland | $120.3K | 1,885 | 541 |
| Wisconsin | $119.8K | 1,980 | 516 |
| Oklahoma | $112.0K | 2,126 | 550 |
| Arkansas | $107.5K | 2,074 | 475 |
| West Virginia | $95.9K | 2,360 | 542 |
| Kentucky | $93.0K | 1,951 | 503 |
| South Carolina | $72.5K | 1,523 | 433 |
| Nevada | $69.4K | 1,173 | 373 |
| Minnesota | $67.2K | 971 | 285 |
| Connecticut | $64.5K | 1,157 | 318 |
| Hawaii | $58.4K | 947 | 272 |
| Delaware | $53.1K | 764 | 205 |
| Oregon | $52.4K | 985 | 280 |
| New Mexico | $50.6K | 682 | 205 |
| Colorado | $45.1K | 787 | 233 |
| Mississippi | $44.6K | 981 | 245 |
| Rhode Island | $42.9K | 748 | 165 |
| Kansas | $39.2K | 867 | 213 |
| Utah | $33.6K | 479 | 155 |
| Iowa | $32.8K | 627 | 160 |
| Maine | $18.7K | 300 | 89 |
| New Hampshire | $16.0K | 262 | 78 |
| Idaho | $15.1K | 290 | 74 |
| Nebraska | $12.3K | 269 | 69 |
| District of Columbia | $11.8K | 189 | 49 |
| North Dakota | $10.1K | 151 | 46 |
| Montana | $7.8K | 152 | 37 |
| Vermont | $7.0K | 85 | 24 |
| South Dakota | $6.9K | 139 | 35 |
| Alaska | $4.6K | 59 | 21 |
| Wyoming | $3.7K | 61 | 20 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.